Meurer M, Ceric-Dehdari P
Stiftung zur Förderung der Hochschulmedizin in Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.
Dr. A.R. Shamma Medical Center, Jumeira 1, Dubai, Vereinigte Arabische Emirate.
Hautarzt. 2017 Nov;68(11):876-884. doi: 10.1007/s00105-017-4065-6.
Systemic drug treatment of vitiligo is currently limited to predominantly adjuvant measures for increasing the effectiveness of UV light therapy. We here present new approaches for the systemic treatment of vitiligo currently under clinical investigation. These include the α‑MSH-analogue afamelatonide and oral immunosuppressants such as the Janus kinase (JAK) inhibitors which target interferon-α-dependent autotoxic inflammatory reactions. In 2015 the first publications on the successful systemic use of Janus kinase (JAK) inhibitors in vitiligo appeared. The effectiveness was experimentally supported by animal models of vitiligo and by the characterization of new biomarkers in the serum of vitiligo patients. This may significantly expand the range of treatment options for vitiligo. Topical antiinflammatory and UV therapies are still the main components of vitiligo treatment, often in combination. The main outcome parameters include the extent and duration of repigmentation, cessation of spreading, avoidance of side effects and improvement in the quality of life of patients.
白癜风的全身药物治疗目前主要局限于辅助措施，用于提高紫外线光疗的效果。我们在此介绍目前正在临床研究中的白癜风全身治疗新方法。这些方法包括α-MSH类似物阿法美拉酮以及口服免疫抑制剂，如靶向干扰素-α依赖性自身毒性炎症反应的Janus激酶（JAK）抑制剂。2015年，关于Janus激酶（JAK）抑制剂在白癜风全身治疗中成功应用的首批出版物问世。白癜风动物模型以及白癜风患者血清中新生物标志物的特性从实验上支持了其有效性。这可能会显著扩大白癜风的治疗选择范围。局部抗炎和紫外线疗法仍然是白癜风治疗的主要组成部分，且常常联合使用。主要的疗效参数包括色素再生的程度和持续时间、白斑停止扩散、避免副作用以及患者生活质量的改善。
